Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, December 23, 2016
[ Fri, Dec 23rd 2016
] - WOPRAI
[ Fri, Dec 23rd 2016
] - WOPRAI
[ Fri, Dec 23rd 2016
] - WOPRAI
Thu, December 22, 2016
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
[ Thu, Dec 22nd 2016
] - WOPRAI
Anupam Rama Initiated (SRPT) at Buy and Held Target at $40 on, Dec 22nd, 2016
Anupam Rama of JP Morgan, Initiated "Sarepta Therapeutics, Inc." (SRPT) at Buy and Held Target at $40 on, Dec 22nd, 2016.
Anupam has made no other calls on SRPT in the last 4 months.
There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 2 agree with Anupam's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Initiated at Hold on, Thursday, October 27th, 2016
- Mike Guo of "SunTrust Robinson Humphrey" Upgraded from Sell to Hold on, Monday, September 19th, 2016
These are the ratings of the 3 analyists that currently disagree with Anupam
- Alethia Young of "Credit Suisse" Initiated at Buy on, Tuesday, October 18th, 2016
- Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $108 on, Wednesday, September 28th, 2016
- Yun Zhong of "Janney Montgomery Scott" Upgraded from Hold to Strong Buy on, Monday, September 19th, 2016
